Cognition Therapeutics Inc CGTX

$0.68 +0.00 (0.52%)

Valuation

Market cap
64,650,000
Revenue TTM
$0
Net income TTM
$-23,490,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
277,600
Avg volume
490,432
Day's range
$0.65 – $0.70
Shares out
95,101,000
Stochastic %K
52%
Beta
1.84
Analysts
Strong Buy
Price target
$3.33

Price

Company profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, whic...

Show more

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
412 481 2210
Website
https://www.cogrx.com
Address
2500 Westchester Ave., Purchase, United States

Latest news

Stocktwits

Shawshank_book_keeper Nov 14, 4:00 AM
$CGTX wow is all I have to say… I guess anything is possible considering countless antibody studies, a glp 1 enzyme study, and repurposed drugs have failed!! If only we had a Novel first in class MOA oral drug therapy out there. 🤔
0 replies
nostic Nov 13, 8:52 PM
$CGTX 10 minutes left to get your trades in before market close. What is coming on Monday at the CTAD conference could be a gamechanger for CGTX. Why would Cognito pay to be a gold sponsor of the event only to report a miss on its Phase 3 HOPE trial? My guess it will pass, and that will be good for CGTX. An oral pill is easier than wearing a headset for an hour a day, plus it could force the market to reconsider alternative MOAs.
2 replies
Rjcamel2355 Nov 13, 2:40 PM
$CGTX Looks like short interest here is going down a bit, at least for the near term.
0 replies
TwizzlersForSale Nov 13, 7:32 AM
$CGTX After a BTD denial was published hidden in a slideshow’s footnote days after the required deadline to disclose material information to shareholders in 2025 by management, I begin to question if this company + management is as ethical as appears on surface and everyone claims to be. Possibly funneled as much investor funds as possible, hit an ATM, and know regardless of what progress they report, money’s gone. Fishy. Does management care about investors also, at all?… With current valuation anomaly at $0.67 it’s worth researching class action.
2 replies
alcat1973 Nov 11, 9:36 PM
$CGTX News of a grant, private funding or even fda fast track are all feasible here. Don't let the drop in share price or delisting notification distract your thinking. There is nothing ou currently available to treat this large segment of patients in desperate need of a solution. You will thank me next year.
2 replies
TwizzlersForSale Nov 11, 4:14 PM
$CGTX I don’t think anyone questions if Z works.. trials have shown the science works. What I think investors are questioning is price. I’ve seen drugs receive fda approval and hit the market just for the price to do nothing… some tank. Because after years of diluting price, years of reverse splits and non-price-action;an fda approval doesn’t miraculously save shitty price action. I think we are getting warnings here seeing CGTX does not respond to positive trial data / progression enough that the stock begins to turn in the right direction. So… an investment in a promising small cap biotech that may very well have positive readout data and fda approval is great for patients but yields nothing for shareholders. It happens, and as of now is also the case here…
7 replies
GibsonFlyingV Nov 11, 3:01 PM
$CGTX just enjoying the dip and buying more. To everyone blaming Lisa; 1. Other potential treatments have failed. 2. The NIH backed this. 3. Lisa owns 1,754,702 shares. Her spouse owns more than 38,000 shares. 4. The science hasn’t changed.
3 replies
Shawshank_book_keeper Nov 11, 7:22 AM
$CGTX definition of insanity according to Einstein is doing the same thing over and over expecting different results… let me take a guess.. acumen pharma failed their phase 2 AD trial with another Ig conjugate?? Can’t be as crazy as the failed trial by Novo Nordisk using semaglutide for early onset Alzheimer’s 🤣
0 replies